Comparative Pharmacology
Head-to-head clinical analysis: ANTIVERT versus COMPAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANTIVERT versus COMPAZINE.
ANTIVERT vs COMPAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antivert (meclizine) is a piperazine H1 histamine receptor antagonist with central anticholinergic and sedative properties. It suppresses the chemoreceptor trigger zone and labyrinthine apparatus, reducing vestibular stimulation and vertigo.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
25-100 mg orally daily in divided doses 2-4 times daily; maximum 400 mg/day.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
None Documented
None Documented
Terminal elimination half-life is 35–50 hours in adults; prolonged in renal impairment.
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
Primarily renal (urine) as unchanged drug and metabolites; biliary excretion is minimal. Approximately 80% excreted unchanged in urine.
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Category C
Category C
Antiemetic
Antipsychotic (Phenothiazine) / Antiemetic